Ironwood Pharmaceuticals: PharmaVitae Report

This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Features and benefits

• Gain insight into Ironwood Pharmaceuticals' strategic outlook
• Analyze company sales forecasts by product

Highlights

Linaclotide is Ironwood Pharmaceuticals' most advanced product candidate. This drug is an orally administered guanylate cyclase type-C (GC-C) agonist for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). It is the main driver for the company.

Your key questions answered

• Benchmark Ironwood Pharmaceuticals' performance against key rivals in the prescription pharmaceutical sector
• Assess how successful Ironwood Pharmaceuticals will be in obtaining marketing approval for its first product

Table Of Contents

ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats

SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
IBS-C and CC background
Linaclotide
Key competitors
Clinical trials
Commercial impact of trial results
Key forecasting assumptions
Early-stage products
IW-6118
MD-0727
IW-1221
BNC-210

FINANCIAL ANALYSIS
Financial performance overview
Operating costs and profit analysis, 2004–10
Operating costs and profit analysis, 2010–16

APPENDIX
References
Exchange rates

List Of Tables

Table: Key Ironwood corporate relationships
Table: Ironwood product portfolio overview ($m), 2010–16
Table: Ironwood Pharmaceuticals’ Phase III clinical trial program included four pivotal trials and two safety studies
Table: Linaclotide US sales forecast model
Table: Ironwood operating revenue/cost analysis ($m), 2004–10
Table: Ironwood operating revenue/cost analysis ($m), 2010–16
Table: Exchange rates, 2011

List Of Figures

Figure: PharmaVitae Explorer
Figure: SWAT analysis
Figure: Linaclotide sales ($m) and growth rate (%), 2010–16
Figure: Ironwood key product sales ($m), 2010–16
Figure: Ironwood operating/cost performance ($m), 2004–16